Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study by Ren, Zhenggang, Prof, Xu, Jianming, Prof, Bai, Yuxian, Prof, Xu, Aibing, Prof, Cang, Shundong, Prof, Du, Chengyou, Prof, Li, Qiu, Prof, Lu, Yinying, Prof, Chen, Yajin, Prof, Guo, Yabing, Prof, Chen, Zhendong, Prof, Liu, Baorui, Prof, Jia, Weidong, Prof, Wu, Jian, Prof, Wang, Junye, Prof, Shao, Guoliang, Prof, Zhang, Bixiang, Prof, Shan, Yunfeng, Prof, Meng, Zhiqiang, Prof, Wu, Jianbing, Prof, Gu, Shanzhi, Prof, Yang, Wei, Prof, Liu, Chao, Prof, Shi, Xuetao, Prof, Gao, Zhenyuan, Prof, Yin, Tao, Prof, Cui, Jiuwei, Prof, Huang, Ming, Prof, Xing, Baocai, Prof, Mao, Yilei, Prof, Teng, Gaojun, Prof, Qin, Yanru, Prof, Wang, Jinhai, Prof, Xia, Feng, Prof, Yin, Guowen, Prof, Yang, Yong, MD, Chen, Mingxia, MD, Wang, Yan, MD, Zhou, Hui, MD, Fan, Jia, Prof

Get full text

Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised,... by Huang, Jing, Prof, Xu, Jianming, Prof, Chen, Yun, MD, Zhuang, Wu, MD, Zhang, Yiping, Prof, Chen, Zhendong, Prof, Chen, Jia, Prof, Zhang, Helong, Prof, Niu, Zuoxing, Prof, Fan, Qingxia, Prof, Lin, Lizhu, Prof, Gu, Kangsheng, Prof, Liu, Ying, MD, Ba, Yi, Prof, Miao, Zhanhui, MD, Jiang, Xiaodong, MD, Zeng, Ming, Prof, Chen, Jianhua, Prof, Fu, Zhichao, MD, Gan, Lu, MD, Wang, Jun, Prof, Zhan, Xianbao, Prof, Liu, Tianshu, Prof, Li, Zhiping, Prof, Shen, Lin, Prof, Shu, Yongqian, Prof, Zhang, Tao, PhD, Yang, Qing, MD, Zou, Jianjun, MD

Get full text

Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial by Qin, Shukui, Prof, Ren, Zhenggang, Prof, Meng, Zhiqiang, Prof, Chen, Zhendong, Prof, Chai, Xiaoli, Prof, Xiong, Jianping, Prof, Bai, Yuxian, Prof, Yang, Lin, Prof, Zhu, Hong, MD, Fang, Weijia, Prof, Lin, Xiaoyan, Prof, Chen, Xiaoming, MD, Li, Enxiao, Prof, Wang, Linna, MD, Chen, Chunxia, MSc, Zou, Jianjun, MD

Get full text

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updat... by Goldman, Jonathan W, MD, Dvorkin, Mikhail, MD, Chen, Yuanbin, MD, Reinmuth, Niels, MD, Hotta, Katsuyuki, Prof, Trukhin, Dmytro, MD, Statsenko, Galina, MD, Hochmair, Maximilian J, MD, Özgüroğlu, Mustafa, Prof, Ji, Jun Ho, MD, Garassino, Marina Chiara, MD, Voitko, Oleksandr, MD, Poltoratskiy, Artem, MD, Ponce, Santiago, MD, Verderame, Francesco, MD, Havel, Libor, MD, Bondarenko, Igor, Prof, Każarnowicz, Andrzej, MD, Losonczy, György, Prof, Conev, Nikolay V, MD, Armstrong, Jon, MSc, Byrne, Natalie, BSc, Thiyagarajah, Piruntha, MD, Jiang, Haiyi, MD, Paz-Ares, Luis, Prof

Get full text

Metabolic syndrome and salt sensitivity of blood pressure in non-diabetic people in China: a dietary intervention study by Chen, Jing, Dr, Gu, Dongfeng, Prof, Huang, Jianfeng, MD, Rao, Dabeeru C, Prof, Jaquish, Cashell E, PhD, Hixson, James E, Prof, Chen, Chung-Shiuan, MS, Chen, Jichun, MD, Lu, Fanghong, Prof, Hu, Dongsheng, Prof, Rice, Treva, PhD, Kelly, Tanika N, PhD, Hamm, L Lee, Prof, Whelton, Paul K, Prof, He, Jiang, Prof

Get full text

Tobacco smoking and risks of more than 470 diseases in China: a prospective cohort study by Chan, Ka Hung, DPhil, Wright, Neil, PhD, Xiao, Dan, Prof, Guo, Yu, MSc, Chen, Yiping, DPhil, Du, Huaidong, PhD, Yang, Ling, PhD, Millwood, Iona Y, DPhil, Pei, Pei, BSc, Wang, Junzheng, BSc, Turnbull, Iain, MRCP, Gilbert, Simon, MSc, Avery, Daniel, MSc, Kartsonaki, Christiana, DPhil, Yu, Canqing, PhD, Chen, Junshi, Prof, Lv, Jun, Prof, Clarke, Robert, Prof, Collins, Rory, Prof, Peto, Richard, Prof, Li, Liming, Prof, Wang, Chen, Prof, Chen, Zhengming, Prof

Get full text